Case Assessment: 68-Year-Old Patient With MCL

Diagnosing MCL and Making Informed Treatment Decisions

Initiating Therapy for Mantle Cell Lymphoma

Relapsed Mantle Cell Lymphoma Treatment Landscape

Administration of BTK Inhibitors for Mantle Cell Lymphoma

BTK Inhibitor Toxicities in Mantle Cell Lymphoma

BTK Inhibitors in MCL: Long-Term Safety & Efficacy Data

Next Steps in Relapsed/Refractory Mantle Cell Lymphoma

Case: A 68-Year-Old Male with Mantle Cell Lymphoma

A 68-year-old man presented with generalized lymphadenopathy, fatigue and an unintentional 8-lb weight loss

LDH 345 U/I, ANC 3500/mm3, beta-2-microglobulin 4.4 µg/L, leukocytes, 5.98 X 109/L, hemoglobin 9.6 gm/dL

Immunocytochemistry: cyclin D1+, CD5+, CD20++

BMB positive for lymphoid cells with cyclin D1

PET/CT scan showed widespread lymphadenopathy in numerous nodal regions including left mesenteric (3.4 cm), bilateral axillary (3.9 cm, 5.3 cm), and cervical (5.1 cm)

Ann Arbor stage IV; MIPI score 6.3; ECOG PS 1



Patient was started on bendamustine + rituximab

At 9 months the patient had clinical disease relapse

He was started on ibrutinib 560 mg PO qDay

Imaging at 12-week follow-up showed no evidence of disease

Case Based Peer Perspectives

Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.